Ausgabe 4/2013
Inhalt (19 Artikel)
Multicolor lineage tracing methods and intestinal tumors
Hirotsugu Yanai, Toshihiro Tanaka, Hiroo Ueno
Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease
Yuki Kawano, David E. Cohen
Physiological roles of dietary glutamate signaling via gut–brain axis due to efficient digestion and absorption
Kunio Torii, Hisayuki Uneyama, Eiji Nakamura
Kampo medicines for gastrointestinal tract disorders: a review of basic science and clinical evidence and their future application
Kazunari Tominaga, Tetsuo Arakawa
Association between metabolic syndrome and prevalence of gastroesophageal reflux disease in a health screening facility in Japan
Masatoshi Niigaki, Kyoichi Adachi, Kazuya Hirakawa, Kenji Furuta, Yoshikazu Kinoshita
Microscopic esophagitis distinguishes patients with non-erosive reflux disease from those with functional heartburn
Edoardo Savarino, Patrizia Zentilin, Luca Mastracci, Pietro Dulbecco, Elisa Marabotto, Lorenzo Gemignani, Luca Bruzzone, Nicola de Bortoli, Anna Chiara Frigo, Roberto Fiocca, Vincenzo Savarino
Peptic ulcers after the Great East Japan earthquake and tsunami: possible existence of psychosocial stress ulcers in humans
Takeshi Kanno, Kastunori Iijima, Yasuhiko Abe, Tomoyuki Koike, Norihiro Shimada, Tatsuya Hoshi, Nozomu Sano, Motoki Ohyauchi, Hirotaka Ito, Tomoaki Atsumi, Hidetomo Konishi, Sho Asonuma, Tooru Shimosegawa
Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
Yosui Tamaki, Yukiomi Nakade, Taeko Yamauchi, Yuichi Makino, Shiro Yokohama, Mitsuyoshi Okada, Kazunobu Aso, Hiroyuki Kanamori, Tomohiko Ohashi, Ken Sato, Haruhisa Nakao, Masakazu Haneda, Masashi Yoneda
The role of peroral video cholangioscopy in patients with IgG4-related sclerosing cholangitis
Takao Itoi, Terumi Kamisawa, Yoshinori Igarashi, Hiroshi Kawakami, Ichiro Yasuda, Fumihide Itokawa, Yuui Kishimoto, Masaki Kuwatani, Shinpei Doi, Seiichi Hara, Fuminori Moriyasu, Todd H. Baron
Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus
Toshihide Shima, Hirofumi Uto, Kohjiro Ueki, Toshinari Takamura, Yutaka Kohgo, Sumio Kawata, Kohichiroh Yasui, Hyohun Park, Naoto Nakamura, Tatsuaki Nakatou, Nobuyoshi Tanaka, Atsushi Umemura, Masayuki Mizuno, Junko Tanaka, Takeshi Okanoue
Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C
Reiichiro Kondo, Hirohisa Yano, Osamu Nakashima, Ken Tanikawa, Yoriko Nomura, Masayoshi Kage
Incidence of hepatocellular carcinoma in HCV-infected patients with normal alanine aminotransferase levels categorized by Japanese treatment guidelines
Naoki Harada, Naoki Hiramatsu, Tsugiko Oze, Ryoko Yamada, Mika Kurokawa, Masanori Miyazaki, Takayuki Yakushijin, Takuya Miyagi, Tomohide Tatsumi, Shinichi Kiso, Tatsuya Kanto, Akinori Kasahara, Masahide Oshita, Eiji Mita, Hideki Hagiwara, Yoshiaki Inui, Kazuhiro Katayama, Shinji Tamura, Harumasa Yoshihara, Yasuharu Imai, Atsuo Inoue, Norio Hayashi, Tetsuo Takehara
KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
Stefan Boeck, Andreas Jung, Rüdiger P. Laubender, Jens Neumann, Rosalind Egg, Clara Goritschan, Steffen Ormanns, Michael Haas, Dominik P. Modest, Thomas Kirchner, Volker Heinemann
Body mass index and nonalcoholic fatty liver disease
Shih-Wei Lai, Kuan-Fu Liao
Reply to the letter by Lai et al. regarding “Body mass index is the most useful predictive factor for the onset of nonalcoholic fatty liver disease: a community-based retrospective longitudinal study”
Teruki Miyake, Teru Kumagi, Shinya Furukawa, Masanori Abe, Yoichi Hiasa, Bunzo Matsuura, Morikazu Onji
Esophageal acid exposure still plays a major role in patients with NERD
Edoardo Savarino, Patrizia Zentilin, Vincenzo Savarino
Answers to “The esophageal acid exposure still plays a major role in patients with NERD” by Dr. Savarino
Liping Duan
Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for ‘middle’?
Masaru Enomoto, Akihiro Tamori, Sawako Kobayashi, Shuji Iwai, Hiroyasu Morikawa, Norifumi Kawada
Response to “Treatment guidelines for HCV genotype 1: mono for low, triple for high, and dual for ‘middle’?”
Kazuaki Chayama, C. Nelson Hayes, Waka Ohishi, Yoshiiku Kawakami